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Obese fat pads are frequently undervascularized and hypoxic, lead-
ing to increased ﬁbrosis, inﬂammation, and ultimately insulin re-
sistance. We hypothesized that VEGF-A–induced stimulation of
angiogenesis enables sustained and sufﬁcient oxygen and nutrient
exchange during fat mass expansion, thereby improving adipose
tissue function. Using a doxycycline (Dox)-inducible adipocyte-spe-
ciﬁc VEGF-A overexpression model, we demonstrate that the local
up-regulation of VEGF-A in adipocytes improves vascularization
and causes a “browning” of white adipose tissue (AT), with mas-
sive up-regulation of UCP1 and PGC1α. This is associated with an
increase in energy expenditure and resistance to high fat diet-me-
diated metabolic insults. Similarly, inhibition of VEGF-A–induced
activation of VEGFR2 during the early phase of high fat diet-in-
duced weight gain, causes aggravated systemic insulin resistance.
However, the same VEGF-A–VEGFR2 blockade in ob/ob mice leads
to a reduced body-weight gain, an improvement in insulin sensi-
tivity, a decrease in inﬂammatory factors, and increased incidence
of adipocyte death. The consequences of modulation of angiogenic
activity are therefore context dependent. Proangiogenic activity
during adipose tissue expansion is beneﬁcial, associated with po-
tent protective effects on metabolism, whereas antiangiogenic ac-
tion in the context of preexisting adipose tissue dysfunction leads
to improvements in metabolism, an effect likely mediated by the
ablation of dysfunctional proinﬂammatory adipocytes.
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Adipose tissue (AT) has unique plasticity, illustrated by itsability for rapid and dynamic expansion or reduction in
periods of excess energy exposure or demand to ensure proper
systemic energy homeostasis. AT expansion includes both hyper-
trophic and hyperplastic growth (1, 2). During the progression to
chronic obesity, AT depots undergo profound pathological
changes (3), such as enhanced oxidative damage, ER stress, local
hypoxia, ﬁbrosis, as well as immune cell inﬁltration and in-
ﬂammation; many of these changes ultimately promote the de-
velopment of insulin resistance (3).
However, not all AT expansion is associated with pathological
changes. A subgroup of individuals that we refer to as “metabol-
ically healthy obese”manage to expand their AT mass without the
associated pathological consequences. The concept of “healthy
AT expansion” suggests that fat pads differ largely with respect to
how well they cope with the local tissue growth (3). In contrast to
the pathological expansion widely seen upon weight gain, a healthy
expansion consists of an enlargement of a given fat pad through
recruitment of new adipocytes, along with the adequate de-
velopment of the vasculature, minimal associated ﬁbrosis, and the
lack of hypoxia and inﬂammation (3).
AT is a highly vascularized tissue. Almost all adipocytes are
surrounded by capillaries (4). A functional vascular system is critical
for AT expansion. Themacro- andmicrovasculature in AT supplies
oxygen, nutrients, hormones, and growth factors, supporting ex-
pansion and homeostasis (4). The vasculature is also critical for the
effective local removal of free fatty acids during fasting. Thus, an-
giogenesis has been considered to be a rate-limiting step for fat
tissue expansion (3). Importantly, several crucial angiogenic factors,
such as leptin, adiponectin, HGF-1, angiopoeitin-2, and VEGF-A
are secreted by adipocytes, suggesting an autoregulatory function for
angiogenesis in AT (4). Among them,VEGF-A is the only bona ﬁde
endothelial cell growth factor. VEGF-A accounts for most of the
proangiogenic activity in AT (5, 6). VEGF-A binds to two tyrosine
kinase receptors, VEGF receptors 1 (R1) and 2 (R2), prompting
homo- and heterodimerization and becomes activated through
transphosphorylation. VEGFR2 mediates most of the known cel-
lular responses to VEGF. The function of VEGFR1 is less deﬁned
(7). VEGF-A levels inATare regulated by exercise, hypoxia, insulin,
a subset of cytokines, and several growth factors (8, 9). However,
adipocytes frequently fail to mount a proper response to local
hypoxia and do not produce sufﬁciently high levels of VEGF (10).
To date, a number of reports demonstrate that the disruption of
neovascularization in AT prevents the development of obesity (11,
12). However, despite these efforts, much remains to be learned
about targeting established blood vessels in the metabolically
challenged AT (4, 11) and the role of angiogenesis and its regula-
tion in healthy expanding fat tissue. This is especially true for the
early stages of tissue expansion. Even though the literature has
primarily focused on the inhibition of angiogenesis at later stages of
metabolic dysfunction, we hypothesized that enhanced neo-
vascularization in expanding fat pads should have beneﬁcial effects.
To test this hypothesis, we used a doxycycline (Dox)-inducible
mouse model that allows us to overexpress VEGF-A uniquely in
white adipose tissue at early stages of a high fat diet (HFD) chal-
lenge. We ﬁnd that angiogenesis facilitates healthy fat pad expan-
sion, reﬂected by smaller average size of adipocytes, absence of
hypoxia, minimal ﬁbrosis, and essentially none of the hallmarks of
inﬂammation characteristic of dysfunctional AT. The mice remain
metabolically ﬁt on a HFD, with improved insulin sensitivity and
increased energy expenditure.More importantly, VEGF-A also up-
regulatesUCP-1 and PGC1α levels, prompting white adipose tissue
to assume a phenotype resembling more closely brown adipose
tissue (13). In contrast, when we blocked functional blood vessel
expansion by using the anti-VEGF antibody (Mcr84) that speciﬁ-
cally inhibits binding of VEGF-A to VEGF receptor 2 at the initial
stages of HFD feeding, we found that the mice showed a signiﬁcant
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metabolic impairment and reduced insulin sensitivity. However,
using the neutralizing antibody in ob/ob mice with preexisting
metabolic dysfunction resulted in the opposite effect: the blockade
decreased local inﬂammation in epididymal white adipose tissue
(EWAT), improved insulin sensitivity, and overall metabolic
health. Taken together, these results highlight the complexity of
interfering with angiogenesis in adipose tissue.
Results
Generation of Transgenic Mice with AT-Speciﬁc Expression of VEGF-A.
Fig. S1A shows a schematic representation of the mouse model.
The tetracycline responsive element (TRE)-drivenVEGF-A trans-
genic model has been described previously (14). In our model,
the TRE is regulated by the reverse tetracycline-dependent tran-
scriptional activator (rtTA), whose expression is under the control
of the AT speciﬁc adiponectin promoter (15). VEGF-A in the
double transgenic mouse is induced in the presence of Dox. To
induce VEGF-A within a physiological range, we titrated different
doses of Dox as food admixtures from 600 mg/kg to 60 mg/kg. We
avoided high doses of Dox (600 mg/kg) to circumvent pathological
changes associated with supraphysiological local levels of VEGF.
By titrating the effective doses of Dox, we identiﬁed that lower
levels of Dox (60 mg/kg) induced VEGF-A within a physiological
range without causing edema formation. All subsequent experi-
ments were performed at these lower doses. Expression of
VEGF-A in a number of fat pads was assayed in the presence or
absence of 60 mg/kg Dox treatment. In EWAT, the transgenic
VEGF-A mRNA levels were induced in the Dox-treated double
transgenic mice only, whereas VEGF-A levels were undetectable
in mice carrying either one of the transgenes as well as double
transgenic mice without Dox treatment (Fig. S1B). VEGF-A was
predominantly induced in white adipose tissues (WATs) (Fig.
S1C), whereas only moderate induction was seen in brown AT
(BAT). No induction was observed in other tissues, such as the
liver (Fig. S1C). Circulating VEGF-A levels were not signiﬁcantly
increased (Fig. S1D). Taken together, our system allows inducible
expression of VEGF-A, with expression restricted to ATs.
Overexpression of VEGF-A Promotes Local Angiogenesis in WAT.
Confocal ﬂuorescent imaging reveals that compared with the con-
trol group, a higher vessel density is seen in the subcutaneousWAT
(SWAT) of VEGF-A Tg mice (Fig. 1A). This differential vessel
density is not observed in other tissues, e.g., in BAT (Fig. 1A),
conﬁrming the speciﬁcity of the VEGF-A effect in WAT. We then
examined the levels of endothelial cell marker CD31.mRNA levels
of CD31 were signiﬁcantly induced in SWAT (Fig. 1B). The pri-
mers for q-PCR are listed in Table S1. Immunohistochemical
analysis further conﬁrmed enhanced CD31 staining in transgenic
mice (Fig. 1C). Analysis of SWAT with anti-VEGF R2 antibodies
also revealed an increased signal in the VEGF Tg mice (Fig. 1D).
More importantly, our analysis with antiphospho-speciﬁcVEGFR2
also reveals more signal intensity in the SWATs of Tg mice (Fig.
1D). Activation of VEGF-A receptor 2 is considered to be a critical
mediator of VEGF-A triggered proangiogenic function (16).
Overexpression of VEGF-A in AT Improves Glucose Tolerance and
Insulin Sensitivity in HFD Challenged Mice. VEGF-A Tg mice
weighed slightly less than control mice as we monitored body
weights beyond week 7 (Fig. S2A). The modest body weight dif-
ference is due to a difference in fat mass in the VEGF-A Tg mice
(Fig. S2A). Importantly, there were no signs of vascular leakage or
edema formation, because NMR measurements show no differ-
ence in interstitial ﬂuid in the transgenic mice (Fig. S2A). Both
white fat pads examined (EWAT and SWAT) showed an in-
creased density in vascular perfusion that is apparent, even at the
level of the whole tissue, as judged by the darker color of both
pads (Fig. S2B). The fasting levels of blood glucose and insulin
were lower in transgenic mice (Fig. S2D). Five weeks after the
initial HFD exposure, there were not yet any body weight differ-
ences between the groups. The oral glucose tolerance tests
(OGTTs) demonstrate that in response to the glucose challenge,
glucose tolerance in the VEGF-A Tg mice is signiﬁcantly im-
proved (Fig. 2A). Insulin sensitivity, as measured by insulin tol-
erance tests (ITTs), was also improved in the VEGF-A Tg mice
(Fig. S2C). These results indicate a high degree of metabolic re-
sistance to a HFD challenge upon supplementation of VEGF-A.
Overexpression of VEGF-A in AT Promotes an Increase in Lipid
Clearance and a Decrease in HFD-Induced Hepatic Steatosis. A lipid
tolerance test showed that VEGF-A Tg mice cleared an oral lipid
challenge much more efﬁciently than the littermate controls
(Fig. S3A). Furthermore, both the cholesterol and free fatty acid
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Fig. 1. VEGF-A stimulates angiogenesis in WAT. (A) Functional blood vessels
in SWAT and BAT visualized by tail-injected rhodamine tagged lectin-1 in
VEGF-A Tg and control mice. Blood vessels are shown in red and the nuclei are
in blue, visualized by DAPI staining. The images were captured with confocal
microscope. (B) q-PCR analysis of CD31 in SWAT of VEGF-A Tg and control
mice (n = 4 in controls; n = 5 in VEGF-A Tg). The difference was analyzed by
Student’s t test. *P < 0.05. (C) Immunohistochemical analysis with α-CD31 in
SWAT of VEGF Tg or their littermate controls. (Scale bar, 50 μm.) (D) Immu-
nohistochemical analysis with α-VEGF receptor 2 and α-phosphorylated VEGF
receptor 2 in SWAT in both VEGF Tg and controls. (Scale bar, 50 μm.)
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Fig. 2. VEGF-A Tg mice exhibit an improved metabolic proﬁle. (A) Circu-
lating glucose levels measured during an OGTT (n = 5 per group) 5 wk after
HFD feeding. The difference at each time point was analyzed by Student’s t
test. *P < 0.05; **P < 0.001. (B) Indirect calorimetry was performed in
a CLAMS system by housing mice after HFD plus Dox feeding for 6 wk. VO2
and RER (VCO2/VO2) were calculated from the average results during a 24-h
light and dark cycle. Absolute contributions of carbohydrate and lipid me-
tabolism to total energy expenditure and accumulated food intake were
measured (ACC). *P < 0.05; **P < 0.001.
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(FFA) content in the livers were signiﬁcantly lower in the VEGF-A
Tg mice. Liver triglyceride (TG) levels also show a trend toward
a decrease (Fig. S3C). H&E staining indicates fewer and smaller
lipid droplets in hepatocytes from VEGF-A transgenic mice
(Fig. S3D). Systemically, the improvements in lipid metabolism
resulted in lowered plasma FFAs (Fig. S3B). The improvements in
lipid parameters are, at least in part, due to higher levels of lipo-
protein lipase (LPL), because mRNA levels of LPL in both adipose
tissue and in the heart increased signiﬁcantly (Fig. S3E). Collec-
tively, these data highlight that ATVEGF overexpression results in
signiﬁcant systemic improvements in lipid metabolism.
Overexpression of VEGF-A in AT Leads to an Increase in Energy
Expenditure. The energy expenditure in metabolic chambers data
indicate that the rate of oxygen consumption (VO2) was signiﬁ-
cantly increased in the VEGF Tg mice (Fig. 2B). They also had
a signiﬁcantly higher respiratory exchange rate (RER), in-
dicating that a higher proportion of energy expended in the
transgenics derives from glucose metabolism (Fig. 2B). However,
the absolute rate of lipid oxidation is similar between VEGF Tg
and their littermate controls, whereas the use of carbohydrate
is increased in the VEGF Tg mice (Fig. 2B). VEGF-A over-
expression leads therefore to an increase in energy expenditure,
and the increase is primarily driven by an increase in carbohy-
drate metabolism. Moreover, VEGF Tg mice have an increase
in food intake (Fig. 2B), further illustrating the higher energy
turnover in light of the weight differences.
Overexpression of VEGF-A Decreases Adipocyte Size and Enhances
a “Brown Adipose” Phenotype in WAT. Histological examination
revealed dramatic differences, including smaller-sized adipocytes
in WATs of VEGF Tg mice (Fig. 3A and Fig. S4A). Further-
more, the reduction of lipid depots and a more multilocular
appearance of the SWAT cells are characteristic features of BAT
(Fig. 3A; and see Fig. S6B). Indeed, both qPCR and Western
blotting revealed marked increases in PGC-1α and UCP-1 levels
(Fig. 3 B and C and Fig. S4C), lending further support for a
browning of WATs in the VEGF-A Tg mice (13, 17). We also
observed that mRNA levels for PPARγ and ZFP423 were un-
affected (Fig. S4B). In VEGF Tg mice, leptin levels in both AT
and serum were signiﬁcantly decreased (Fig. S5A). Even though
there was no difference at the level of adiponectin mRNA (Fig.
S5B), circulating adiponectin levels decreased slightly, whereas
intracellular pools were increased (Fig. S5 C and D), suggestive
of a reduction in adiponectin secretion.
Overexpression of VEGF-A Suppresses Hypoxia and Fibrosis and
Reduces Local Inﬂammation in WAT During HFD Exposure. Immu-
nohistochemical assessment of local hypoxia using a hypoxyprobe
indicates that hypoxia in WATs is signiﬁcantly reduced in trans-
genic mice (Fig. 4A). Consistent with the reduction of hypoxic
conditions, there is a signiﬁcant reduction in the levels of HIF1α
associated with induced VEGF-A overexpression (Fig. 4B). The
ﬁbrotic collagens III and VI (Col3 and Col6) are reduced (Fig.
4B). Interestingly, matrix metalloprotease-1 (MMP-1), one of the
key enzymes facilitating the digestion of collagens in AT, was
signiﬁcantly induced inVEGFTgmice (Fig. 4B). In line with these
observations, a trichrome stain of SWAT and EWAT indicates
that the extracellular matrix (ECM) accumulation is signiﬁcantly
reduced in the transgenic animals (Fig. S6B).
We further observed signiﬁcantly decreased expression of in-
ﬂammatory factors, such as IL6, F4/80, TNFα, and SAA3 by
qPCR in EWAT of VEGF-A Tg mice (Fig. 4C). In line with
these transcriptional changes, the levels of the generic plasma
inﬂammatory marker serum amyloid A (SAA) were signiﬁcantly
reduced in VEGF Tg mice (Fig. S6A). Immunohistochemical
analysis of both SWAT and EWAT with an anti-F4/80 antibody
further conﬁrms a reduced frequency of “crown-like” structures
surrounding adipocytes in the VEGF-A Tg mice (Fig. 4D and
Fig. S6C). Collectively, we conclude that local overexpression of
VEGF-A in AT prevents tissue dysfunction.
Angiogenesis-Inhibitor Treatment During Early Stages of HFD-Induced
Weight Gain Aggravates Systemic Metabolic Health. To investigate
the “loss-of-function” effect of angiogenesis, we used anti-VEGF
monoclonal antibody Mcr84. This monoclonal antibody binds
mouse VEGF and selectively blocks VEGF from interacting with
VEGFR2 (18). We treated 6-wk-old wild-type mice withMcr84 or
control IgG just before and throughout a 6-wk time course of HFD
feeding. Whereas food intake, weight gain (Fig. S7A), and dis-
sected fat pad size did not differ between groups, we observed an
impaired response to the HFD in the Mcr84-treated mice. The
Mcr84-treated mice required higher insulin to control their glu-
cose levels during an OGTT (Fig. 5B), even though a comparable
rate of glucose clearance wasmaintained, along with a reduction in
lipid clearance (Fig. 5C). As a reﬂection of the dysfunctional ATs,
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Fig. 3. VEGF-A Tg mice have smaller white adipocytes with BAT-like prop-
erties. (A) H&E staining of SWAT of VEGF-A Tg mice after HFD plus Dox
feeding for 8 wk. (Scale bars, 50 μm.) (B) q-PCR analysis of PGC-1α and UCP-1
in EWAT of VEGF-A Tg and their littermate controls. The readings are nor-
malized to hypoxanthine phosphoribosyltransferase (HPRT). *P < 0.05; **P <
0.001. (C) Western blot analysis for both PGC-1α and UCP-1 in WAT of VEGF
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Control VEGF TG
Hypoxia probe 
0
10
20
HIF1α
**
0
5
10 Col6
**
0
20 Col3 
*
0
100
MMP1
*
TNFα
0
20
40
*
0
10
20
F4/80
*
0
50 SAA3
*
0
10
20
*
IL6
Control VEGF TG
B
A C
D
VEGF TGControl 
Fig. 4. VEGF-A overexpression ameliorates hypoxia, ﬁbrosis, and in-
ﬂammatory responses in WAT induced by HFD. (A) Immunohistochemical
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the circulating adiponectin levels were lower in Mcr84-treated
mice (Fig. S7C). In an attempt to assess metabolic ﬂexibility, we
measured FFAs in the fed and fasted state. Control mice display
the anticipated increase and decrease of FFAs during the fasted
and fed state, respectively. However, this dynamic regulation was
absent in the Mcr84-treated mice (Fig. 5D). As expected, Mcr84-
treated WAT displays a reduction in the amount of ﬂuorescently
labeled lectin (Fig. 5A).We also observed that themRNA levels of
CD31 decreased in SWAT but not in livers (Fig. S7B), indicating
that angiogenesis inhibition is primarily affecting fat tissues. Fur-
thermore, there was an increase in macrophage inﬁltration in
EWAT in the Mcr84-treated mice (Fig. S7D). Despite similar
overall fat pad weight, we observed an increase in average adi-
pocyte cell size in the Mcr84-treated mice (Fig. S7D).
Angiogenesis-Inhibitor Treatment in Dysfunctional AT Minimizes
Body-Weight Gain and Enhances Insulin Sensitivity in the Context of
ob/ob Mice. Our previous observations demonstrated the meta-
bolically challenged state of WAT in adult ob/ob mice (10). We
therefore selected 6-wk-old ob/ob mice as our model. During
a 3-wk treatment regimen, Mcr84-treated ob/ob mice gained
slightly less body weight than their control IgG-treated litter-
mates (Fig. S8A). Furthermore, the Mcr84-treated ob/ob group
displayed a trend toward improvement of glucose-tolerance
compared with the control group (Fig. S9B). Upon examination
of acute fasting serum parameters, circulating FFA levels were
signiﬁcantly lower in the Mcr84-treated ob/ob mice compared
with control IgG-treated mice (Fig. S9C). Circulating glucose
levels following an overnight fast were lower in Mcr84-treated
ob/ob mice compared with controls (Fig. S9C). Furthermore, the
mRNA expression levels of the macrophage marker F4/80 sig-
niﬁcantly decreased in the Mcr84-treated mice (Fig. S9D).
Consistent with these observations, immunoﬂuorescence
staining of EWAT shows that the anti–Mcr84-treated animals
displayed a marked reduction in vascular density (Fig. S9A).
Similarly, the mRNA levels of CD31were signiﬁcantly down-
regulated in EWAT of anti–Mcr84-treated ob/ob mice (Fig.
S8B). We also found a dramatic increase in adipocyte death as
judged by the number of perilipin-negative lipid droplets in the
AT of Mcr84-treated mice compared with control (Fig. S9E).
Discussion
Angiogenesis is an integral component of adipose tissue physiology
(12), even under conditions when weight is stable. In the past two
decades, numerous proangiogenic factors, such as VEGF-A, leptin,
adiponectin, angiopoietin-2, monobutyrin, FGF-2, and hepatocyte
growth factor (HGF) have been identiﬁed in both WAT and BAT
(3). Importantly, these factors were also found to be regulated by
different physiological and pathological conditions. For example,
VEGF-A levels in both local fat pads and circulation are up-regu-
lated by hypoxia, high insulin levels, and exercise (3, 9). However,
the complex crosstalk between angiogenesis and adipogenesis and
the resulting metabolic effects are not well understood. In this study,
we used an AT-speciﬁc, inducible VEGF-A expression system to
delineate the process in detail. We induced VEGF-A expression
upon initiating a HFD exposure, using a relatively low Dox con-
centration (60 mg/kg) to achieve a physiologically relevant degree of
VEGF-A overexpression from adipose tissue. As a major endo-
thelial cell regulator (16), VEGF-A enhances VEGFR2 phosphor-
ylation and triggers angiogenesis, as reﬂected by an enhancement in
vascular density in the WAT. Phenotypically, this results in global
improvements in all aspects examined as they relate to glucose and
lipid metabolism. The underlying mechanism for these improve-
ments is likely to be related to the reduced hypoxia that is prevailing
in the transgenic mice, paralleled by a lack in ﬁbrosis and minimum
local inﬂammation in the WAT of VEGF-A transgenic mice.
The transgenic mice consumed more oxygen and generated
more carbon dioxide, suggesting they exhibit higher energy ex-
penditure. Transgenic animals also had signiﬁcantly higher RER
values. Histological examination of the transgenic mice demon-
strated a BAT-like phenotype in the WAT depots, particularly in
SWAT. Along with the visually apparent changes, both qPCR and
immunoblotting analysis of WAT revealed signiﬁcant increases in
PGC-1α and UCP-1 levels, which may be the key drivers for the
BAT-like appearance of theWAT. Of high interest in this context
is UCP-1, a protein that uncouples electron transport from ATP
production to produce heat (19), thereby offering an explanation
for the increased energy expenditure. An overall increase in the
mitochondrial mass is stimulated by PGC-1α. Consistent with
these ﬁndings is the observation by Xue et al. who reported that
cold exposure in mice leads to a brown-like phenotype in WAT;
they further found that AT up-regulates VEGF levels under these
conditions and switches the fat pads to a more proangiogenic
proﬁle upon cold exposure (17). In this context, our observations
underline the key role that VEGF-A plays in this process, because
we observe a similar transition to a “BAT-like” phenotype in the
presence of VEGF-A alone without an associated cold exposure.
Dysfunctional AT per se can lead to systemic insulin resistance
(3). The subsequent increased release of free fatty acids and
proinﬂammatory factors trigger an elevated degree of lipotoxicity in
nonadipose tissue organs, particularly in liver and muscle (20).
Indeed, we observed an increase of serum FFA and TG levels in
both serum and liver in the control mice after HFD feeding.
However, the transgenic mice showed lower lipotoxic side effects
and normal liver histology. Because the VEGF transgene expres-
sion remained local within adipose tissue, it did not affect angio-
genesis in the liver. Therefore, the improvements in lipid
metabolism in the liver are a direct consequence of the beneﬁcial
effects of VEGF elevation in adipocytes. The underlying mecha-
nisms leading to the unexpected decrease in circulating adiponectin
levels, potentially as a function of impaired release from adipocytes
in the VEGF-A TG model, are currently under investigation.
In contrast, blocking angiogenesis at early stages of obesity
during the increase in AT mass is rather different. We treated
wild-type mice with the VEGF-A Mcr84 antibody or control
IgGs just before and throughout a 6-wk time course of high fat
diet feeding. Mcr84-treated WAT displays a reduction in vas-
cular density, whereas liver and other tissues were unaffected.
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This indicates that our antiangiogenesis treatment is effective
enough to have an impact on vascular density, but only in AT
despite systemic exposure to antibody. This further highlights
that adipose tissue is one of the tissues that constantly remodels
its vasculature. It is thereby particularly susceptible to an im-
balance of proangiogenic signals. Despite similar overall fat pad
weights, we observed an increase in adipocyte cell size in the
antibody-treated mice. Furthermore, there was an increase in
macrophage inﬁltration in EWAT. Whereas food intake, weight
gain, and dissected fat pad size did not differ between groups,
we observed that Mcr84-treated mice required higher insulin to
control their glucose levels during an OGTT, and their lipid
clearance ability was also decreased. As an additional indicator
of the dysfunctionality of fat cells, the circulating adiponectin
levels displayed a trend toward a decrease. Importantly, whereas
control mice displayed the anticipated increase and decrease of
FFA during feeding/fasting, this dynamic regulation was absent
in the Mcr84-treated mice. This clearly highlights the relevance
of proper vascular expansion during weight gain.
Several reports have suggested that antiangiogenic treatment
regimens reduce body weight in murinemodels of obesity and lead
to improvements in some aspects of the metabolic syndrome (21–
23). Thus, both enhancing AT angiogenesis in our present study
and inhibiting AT angiogenesis are paradoxically associated with
an improvement in systemic metabolism. Although the underlying
mechanism for angiogenesis inhibitor-induced improvements
on metabolic parameters is still not clear, we hypothesized that
blocking the capacity for angiogenesis may have different out-
comes, dependent on the stage of obesity. Previous studies with
angiogenesis inhibitors were performed in extremely obese mice,
not in the early stages of diet-induced weight gain. Moreover,
dysfunctional adipocytes display an inefﬁcient TG storage. The
elevated lipolytic rate under these conditions is less capable of
sequestering and neutralizing excess FFAs. This leads to ectopic
lipid storage, increased inﬂammation, and further deterioration of
systemic insulin sensitivity (20). Blocking the capacity for angio-
genesis in the context of severe obesity induces adipocyte apo-
ptosis (21). We suggest that the largest and most dysfunctional
adipocytes are most likely to undergo angiogenesis-inhibitor–in-
duced apoptosis compared with smaller adipocytes, because they
already are under hypoxic conditions. By blocking the capacity
for angiogenesis, angiogenesis inhibitors may reduce the proin-
ﬂammatory contributions of an excessive number of dysfunctional
adipocytes on systemicmetabolism. Indeed, our experiments in ob/
ob mice support this hypothesis: treating ob/ob mice with Mcr84
that selectively blocks VEGF-A from activating VEGFR2 causes
increased adipocyte death. In parallel, the systemic serum in-
ﬂammatory factor SAA decreases signiﬁcantly. Systemically, the
mice exhibit weight loss with a concomitant improvement in glu-
cose tolerance. We selected 6-wk-old ob/obmice as an “unhealthy
expansion model,” such that we and others have demonstrated
that WAT in these mice undergoes hypoxia along with induced
HIF1α expression, which in turn stimulates ﬁbrosis and local in-
ﬂammation (10, 24). Indeed, other studies have similarly suggested
that VEGF inhibitor treatment, which speciﬁcally targets
VEGFR2, decreases AT mass following HFD (7).
In conclusion, our ﬁndings highlight how manipulation of an-
giogenesis at various stages of obesity development differentially
affects whole AT physiology and energy expenditure. Speciﬁcally,
stimulation of angiogenesis at an early stage of obesity has ben-
eﬁcial effects in mice, whereas angiogenesis inhibition after the
fact also supports improvements, but with a different underlying
mechanism. Our studies pave the way for a better understanding
of these phenomena that give rise to profound effects of angio-
genesis on overall healthy condition and energy expenditure.
Given that this aspect of adipose tissue physiology translates well
to the clinical setting, it is tempting to speculate whether it is
worthwhile to supplement patients with VEGF-A in the obese
state. However, as with many other pharmacological inter-
ventions aimed at improving adipose tissue health, we have to be
concerned that the same strategies will enhance the growth of
solid tumors, as they rely on similar rate-limiting steps for ex-
pansion as a growing adipose tissue pad.
Materials and Methods
Animals. TRE–VEGF-A transgenicmice have beendescribed previously (14).Mice
in the original Friend leukemia virus B strain (FVB) background have been
backcrossed to pure C57BL/6 mice (Jackson Laboratories) for eight generations
to obtain a pure C57BL/6 background. ob/ob experiments were performed on
mice on a pure FVB background. Adiponectin-rtTA transgenic mice were on
a pure C57BL/6 background. These mice were crossed with TRE–VEGF-Amice to
generate theAT-speciﬁc Dox-inducibleVEGF-A transgenicmice. All experiments
were conducted using littermate-controlled male mice and were started when
they were 5 wk old. Mice were housed in cages with 12-h dark–light cycle with
free access to water and regular chow. All animal experiments were performed
with the approval of the institutional animal care and use committee of Uni-
versity of Texas Southwestern Medical Center at Dallas.
Mcr84 (Anti-VEGF) Treatment. The VEGF-speciﬁc antibody Mcr84 had been
described previously (18). For the treatment of wild-type mice, 6-wk-old
male C57B/6 wild-type mice were injected intraperitoneally (i.p.) with Mcr84
or isotype control IgGs (0.2 mg per mouse) twice per week. The injection
began just before the introduction of HFD and continued for 6 wk. Food
intake and body weights were monitored throughout the entire time
course. An oral glucose and lipid tolerance test were performed after 4 and
5 wk on HFD, respectively. At week 6, the mice were fasted for 3 h and
anesthetized with isoﬂurane. Tissues and sera were collected for analysis.
Similarly, for the experiments in ob/obmice, 6-wk-old male ob/obmice were
injected i.p. with either control IgG or mcr84 twice per week for 3 wk.
Statistical Analysis. All results are given as means ± SEM. Differences between
two groups were examined for statistical signiﬁcance with Student’s t test.
Signiﬁcance was accepted at a P value of <0.05.
Additional Materials and Methods. Please refer to SI Materials and Methods.
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